Ocular Therapeutix shares are trading higher after the company announced the FDA agreed to a Special Protocol Assessment Agreement Modification for its pivotal Phase 3 SOL clinical trial of AXPAXLI in wet AMD.
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix's stock price has risen following the announcement that the FDA has agreed to a Special Protocol Assessment Agreement Modification for its Phase 3 SOL clinical trial of AXPAXLI in wet AMD.
January 25, 2024 | 6:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's announcement of the FDA's agreement to a protocol modification for its AXPAXLI Phase 3 trial has positively impacted its stock price.
The FDA's agreement to a Special Protocol Assessment Agreement Modification is a significant regulatory milestone that can lead to increased investor confidence in the company's ability to bring AXPAXLI to market. This news directly impacts Ocular Therapeutix and is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100